Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbix Biosystms ( (TSE:MBX) ) just unveiled an update.
Microbix Biosystems has granted 2,600,000 stock options under its shareholder-approved stock option plan to incentivize and retain its board, executives, and senior managers. The options, exercisable at $0.23 per share after a three-year vesting period and with a five-year life, are subject to TSX approval and allocated across 37 senior personnel, including six independent directors.
Management positions the annual stock option issuance as a core component of total compensation, estimating a quarterly expense of about $24,000, or roughly 2% of overall compensation costs. The company projects potential share dilution of up to 2%, which it expects to largely offset through its normal-course issuer bid, while total outstanding options will rise to 13,830,000 under its rolling plan that permits grants up to 10% of shares outstanding.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.22 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
The score is held down primarily by weakened financial performance (return to losses and negative cash flow) and only mildly supportive technicals (negative MACD and below longer-term averages). The earnings call adds some offset from improving sequential trends, cash collections, and operational initiatives, but near-term revenue/margin uncertainty—especially tied to China—keeps the overall score below average.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a Canadian life sciences innovator that manufactures and exports proprietary biological products for the global diagnostics industry. Its portfolio includes immunoassay antigens, laboratory quality assessment products under the QAPs and QUANTDx brands, and reagents supporting clinical diagnostic workflows, serving diagnostics makers, accreditation bodies, and clinical labs in over 30 countries.
Average Trading Volume: 68,099
Technical Sentiment Signal: Sell
Current Market Cap: C$32.56M
For detailed information about MBX stock, go to TipRanks’ Stock Analysis page.